Literature DB >> 26541176

A comparison of Wharton's jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.

Rasha F El-Demerdash1, Lamiaa N Hammad1, Mohamed M Kamal2, Hala O El Mesallamy2.   

Abstract

AIM: In this study, we investigated the differences between mesenchymal stem cells (MSCs), isolated from umbilical cord blood (UCB-MSCs) and Wharton's jelly (WJ-MSCs) as sources of diabetes mellitus cell therapy.
METHODS: After isolation, both cell types were induced to differentiate into insulin producing cells, then the differentiated cells were assessed genetically and functionally. UCB-MSCs and WJ-MSCs were transplanted in the tail veins of streptozotocin-induced diabetic rats. Blood glucose levels were monitored post-transplantation. RESULTS &
CONCLUSION: Wharton's jelly was more homogeneous, can better differentiate into insulin producing cells in vitro and better control hyperglycemia in diabetic rats in vivo, as compared with UCB. These results indicate that WJ-MSCs represent a potential source of cells in the field of diabetes mellitus cell therapy.

Entities:  

Keywords:  Wharton's jelly; cell banking; cell therapy; diabetes mellitus; mesenchymal stem cells; umbilical cord blood

Mesh:

Year:  2015        PMID: 26541176     DOI: 10.2217/rme.15.49

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  9 in total

Review 1.  Therapeutic potential of mesenchymal stem cells for diabetes.

Authors:  Alvaro Moreira; Samuel Kahlenberg; Peter Hornsby
Journal:  J Mol Endocrinol       Date:  2017-07-24       Impact factor: 5.098

2.  Thrombin Preconditioning Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in Severe Intraventricular Hemorrhage Induced Neonatal Rats.

Authors:  So Yeon Jung; Young Eun Kim; Won Soon Park; So Yoon Ahn; Dong Kyung Sung; Se In Sung; Kyeung Min Joo; Seong Gi Kim; Yun Sil Chang
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

3.  Culture of iPSCs Derived Pancreatic β-Like Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary Trial.

Authors:  Jian Wan; Yan Huang; Pengcheng Zhou; Yibing Guo; Cen Wu; Shajun Zhu; Yao Wang; Lei Wang; Yuhua Lu; Zhiwei Wang
Journal:  Biomed Res Int       Date:  2017-04-05       Impact factor: 3.411

Review 4.  Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.

Authors:  Ammira Al-Shabeeb Akil; Esraa Yassin; Aljazi Al-Maraghi; Elbay Aliyev; Khulod Al-Malki; Khalid A Fakhro
Journal:  J Transl Med       Date:  2021-04-01       Impact factor: 5.531

Review 5.  Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives.

Authors:  Haisen Li; Hao Zhu; Ting Ge; Zhifeng Wang; Chao Zhang
Journal:  Stem Cell Rev Rep       Date:  2021-03-05       Impact factor: 5.739

Review 6.  Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells.

Authors:  Shujing Li; Xianyun Wang; Jing Li; Jun Zhang; Fan Zhang; Jie Hu; Yixin Qi; Baoyong Yan; Quanhai Li
Journal:  Stem Cells Int       Date:  2016-05-17       Impact factor: 5.443

7.  Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers.

Authors:  Dina H Kassem; Mohamed M Kamal; Abd El-Latif G El-Kholy; Hala O El-Mesallamy
Journal:  Stem Cell Res Ther       Date:  2016-08-11       Impact factor: 6.832

Review 8.  Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges.

Authors:  Mohamed M Kamal; Dina H Kassem
Journal:  Front Cell Dev Biol       Date:  2020-01-29

9.  Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study.

Authors:  Dina H Kassem; Mohamed M Kamal
Journal:  Stem Cell Res Ther       Date:  2020-11-16       Impact factor: 6.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.